---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-030085"
form_type: "8-K"
ticker: "GOVX"
cik: "0000832489"
company_name: "GeoVax Labs, Inc."
filed_at: "2026-09-10T20:35:22+00:00"
generated_at: "2026-09-10T20:36:15.488153+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# GeoVax faces Nasdaq delisting hearing Oct 13 over bid price; stock continues trading

## Summary
- Received Nasdaq delisting determination Aug 27, 2026 for failing minimum bid price (Rule 5550(a)(2)).
- Hearing before Nasdaq Hearings Panel scheduled for Oct 13, 2026; suspension/delisting stayed pending hearing.
- Common stock continues trading on Nasdaq Capital Market under GOVX through hearing and any extension.
- Company to present plan to regain compliance; reaffirms GEO-MVA pivotal Phase 3 and Gedeptin oncology progress.
- CEO David Dodd cites vaccine supply resilience and biodefense preparedness as strategic focus.

## SEC filing metadata
- accession: 0001437749-26-030085
- form_type: 8-K
- ticker: GOVX
- cik: 0000832489
- company_name: GeoVax Labs, Inc.
- filed_at: 2026-09-10T20:35:22+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/832489/000143774926030085/0001437749-26-030085-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/832489/000143774926030085/govx20260909_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-030085
- JSON: https://secwatch.observer/filing/0001437749-26-030085.json
- Plain text: https://secwatch.observer/filing/0001437749-26-030085.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.